Litigation Details for Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)
| Docket | See Plans and Pricing | Date Filed | 2015-03-17 |
| Court | District Court, N.D. California | Date Terminated | 2017-08-23 |
| Cause | 28:1338 Patent Infringement | Assigned To | Beth Labson Freeman |
| Jury Demand | Both | Referred To | Nathanael M. Cousins |
| Parties | GENENTECH INC | ||
| Patents | 10,029,011; 7,811,572; 8,080,534; 8,383,122; 8,394,780; 8,461,101; 8,633,149; 8,653,021; 9,023,001 | ||
| Attorneys | Aldo Noto | ||
| Firms | Davis Wright and Tremaine | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Phigenix, Inc. v. Genentech, Inc.
The biologic drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Details for Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-08-08 | 234 | Order | ORDER CONSTRUING CLAIMS IN U.S. PATENT NO. 8,080,534. Signed by Judge Beth Labson Freeman on 8/… U.S. PATENT NO. 8,080,534 …infringement of U.S. Patent No. 8,080,534B2 21 (“the ’534 Patent”). The Court…the ’534 Patent. 23 I. BACKGROUND ON THE ’534 PATENT …It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the | External link to document |
| 2016-09-22 | 257 | ) cell lines. (See, e.g., id., 10:29-11:18.) The '534 14 patent includes separate claims directed…asserted claims 1, 2, and 8 of U.S. Patent No. 8,080,534 (the “'534 patent”) under 6 35 U.S.C. § 112…of the '534 patent are invalid as a matter of law because the 12 '534 patent’s specification… genes. ('534 17 patent (ECF No. 21-1), 6:22-23.) The '534 patent purports to disclose the…disclosed in 13 the parent patent application. See Manual of Patent Examining Procedure § 201.08 ( | External link to document | |
| 2016-10-31 | 290 | Order on Motion for Sanctions | infringement of U.S. Patent No. 8,080,534 17 (“the ’534 patent”). ECF 21. …expression and thus infringes the ’534 patent. Id. Claim 1 of the ’534 patent is …Plaintiff Phigenix, Inc. (“Phigenix”) brings this patent infringement lawsuit against … 23 claims 1, 2, and 8 of the ’534 patent. ECF 21. Kadcyla comprises the antibody trastuzumab… to its 4 patent portfolio, and informed Genentech of its theory | External link to document |
| 2017-02-23 | 327 | Order on Motion for Summary Judgment | infringes certain claims of U.S. Patent No. 8,080,534 (“the ’534 patent”) based on Kadcyla, a drug …named inventor on numerous issued and pending patents and patent 25 applications… including the ’534 patent. First Am. Compl. (“FAC”) ¶ 1, ECF 21. The ’534 patent … 27 3 (the ’534 patent). According to Phigenix, the ’534 patent describes and claims methods…cancer. ’534 patent 16 at 6:56-7:15. The ’534 patent also shows that | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
